The present invention relates to compositions and methods for the prevention
and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a
antibodies for the prevention and treatment of sepsis in humans as well as other
animals. The present invention also relates to methods of generating anti-C5a antibodies
employing C-terminal truncated C5a peptides.